New identity reflects Company’s evolution into an innovative data driven biotech company leveraging MITOLINE™ and mitochondrial carrier biology across oncology and inflammatory metabolic diseases Neve Yarak, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today announced a comprehensive corporate rebranding to Nexentis Technologies Inc. (“ ...

Core Insights - N2OFF, Inc. has announced that its subsidiary MitoCareX Bio has demonstrated preliminary in vitro data showing inhibition of pro-inflammatory responses in human immune cells using its proprietary MITOLINE discovery platform, which targets mitochondrial carriers for inflammatory metabolic diseases [1][2] Industry Overview - The market for inflammatory and inflammatory metabolic diseases is rapidly growing, with anti-inflammatory drugs projected to increase from approximately $122 billion in 2024 to nearly $275 billion by 2034, reflecting a compound annual growth rate (CAGR) of about 8.4% [3] - Small-molecule immunomodulators are expected to expand from around $188 billion in 2025 to over $350 billion by 2035, indicating strong demand for targeted oral anti-inflammatory therapies [3] - Therapeutics for metabolic disorders, including key inflammatory metabolic diseases like diabetes, are estimated to be around $77 billion in 2024 and forecasted to exceed $120 billion by 2030 [3] Company Developments - MitoCareX Bio is utilizing the MITOLINE algorithm to create a focused library of small-molecule candidates, which are being evaluated through proprietary in vitro assays to assess mitochondrial function and inflammatory signaling [2][4] - The MITOLINE algorithm addresses a significant challenge in mitochondrial drug discovery by providing reliable 3D comparative models of mitochondrial carrier proteins, facilitating the identification of novel small-molecule scaffolds [4] - MitoCareX Bio plans to advance its most promising mitochondrial-targeted anti-inflammatory candidates toward pre-clinical studies while expanding its discovery efforts across additional mitochondrial carrier targets [5]

Company Overview - N2OFF, Inc. is a drug discovery company that owns 100% of MitoCareX Bio Ltd., which focuses on developing small-molecule drugs targeting human mitochondrial carriers for inflammatory metabolic diseases [6] - N2OFF is also investing in solar energy assets through a Ready to Build (RTB) business model, currently leading four solar projects across three EU countries [6] MitoCareX Bio Developments - MitoCareX Bio has demonstrated preliminary in vitro data showing inhibition of pro-inflammatory responses in human immune cells using its proprietary MITOLINE discovery platform [1][2] - The company is advancing its most promising mitochondrial-targeted anti-inflammatory candidates toward pre-clinical studies while expanding the MITOLINE-powered discovery engine across additional mitochondrial carrier targets [5] Market Potential - The global market for anti-inflammatory drugs is projected to grow from approximately $122 billion in 2024 to nearly $275 billion by 2034, with a compound annual growth rate (CAGR) of about 8.4% [3] - Small-molecule immunomodulators are expected to expand from around $188 billion in 2025 to over $350 billion by 2035, indicating strong demand for targeted anti-inflammatory therapies [3] - Therapeutics for metabolic disorders, including key inflammatory metabolic diseases, are estimated to be around $77 billion in 2024 and forecasted to exceed $120 billion by 2030 [3] MITOLINE Algorithm - The MITOLINE algorithm addresses a critical bottleneck in mitochondrial drug discovery by providing reliable 3D comparative models of mitochondrial carrier proteins, facilitating the identification of novel small-molecule scaffolds [4] - This platform enables MitoCareX to characterize substrate translocation binding sites for virtual screening campaigns, supporting drug discovery in oncology, autoimmune, and metabolic-inflammatory diseases [4]

Core Insights - N2OFF, Inc. is advancing its European portfolio through a partnership with Solterra Renewable Energy Ltd, focusing on solar energy projects in Germany [1][7] - The flagship German solar project is on track for approval in Q3 2026, with no objections during the public consultation phase [3][4] - An amendment to the development agreement has been executed, providing Solterra with $340,000 in advance funding while reducing development fees, potentially increasing profits by approximately $1.7 million [5][10] Project Development - The permitting process for the German solar project is nearing completion, with a clear development timeline maintained [4] - The project has successfully reduced regulatory risks and improved development economics, enhancing long-term project viability [6][7] Financial Implications - The transaction represents an efficient redeployment of capital, improving project economics and increasing embedded equity value [6] - Enhanced monetization optionality is anticipated, with multiple pathways for value realization expected to begin in H2 2026 [10]

Core Insights - N2OFF, Inc. has completed the acquisition of MitoCareX Bio Ltd., focusing on the precision oncology market and leveraging MitoCareX's proprietary MITOLINE algorithm for drug discovery [1][2][3] Company Overview - MitoCareX Bio Ltd. is a biotechnology company utilizing MITOLINE, an algorithm for 3D modeling of mitochondrial transport proteins, to develop therapies for difficult-to-treat cancers [2][4] - The company targets mitochondrial SLC25 transport proteins, which are crucial in the metabolic reprogramming of aggressive cancers like lung and pancreatic cancer, with a projected global therapeutic market exceeding $50 billion by 2026 [3][4] Strategic Direction - MitoCareX aims to optimize hit-to-lead medicinal chemistry and pharmacokinetic profiling in 2026, with the goal of nominating a preclinical development candidate [5] - The company is exploring strategic collaborations and licensing agreements to expand MITOLINE's applications, creating non-dilutive revenue opportunities [6][7] Long-Term Vision - The long-term strategy includes preparing for IND-enabling studies to transition MitoCareX toward clinical readiness while establishing MITOLINE as a scalable discovery engine [7][8] - MitoCareX's approach combines mitochondrial biology, computational modeling, and precision oncology, positioning it uniquely in the biotech sector [8][9] Innovation and Value Creation - The MITOLINE algorithm enables high-throughput in silico screening of small molecules, accelerating the drug discovery process [4][10] - The company aims to build a repeatable, data-driven discovery platform that transforms mitochondrial biology into sustained innovation and value creation [10][11]

Core Insights - N2OFF, Inc. is making significant advancements in solar energy and energy storage projects across Germany, Italy, and Poland, emphasizing its commitment to the clean energy transition [1][4]. Key Solar and Energy Storage Projects - The Melz Solar PV Project in Germany has a capacity of 111 MWp and has achieved critical milestones, including municipal approval and entering the hearing process for RTB status targeted for 2026 [2][7]. - In Italy, two Battery Energy Storage Systems (BESS) projects in Sicily, each with a capacity of 98 MWp/392 MWh, are in development and expected to reach RTB status by mid-2027 [3][7]. Strategic Investments and Opportunities - N2OFF has allocated €600,000 in debt financing for the Melz BESS integration, with a 7% annual interest rate and a 25% profit-sharing agreement post-loan repayment [4]. - The joint venture with Solterra aims for a total portfolio capacity of approximately 300 MW across Europe, indicating a robust growth strategy in renewable energy [4][5].

Core Viewpoint - N2OFF, Inc. is expanding its Melz solar project by integrating a large-scale battery energy storage system (BESS), which is expected to enhance revenue and provide higher returns to stockholders [1][5]. Financial Aspects - N2OFF and other lenders provided €600,000 in additional funding to Solterra at a 7% annual interest rate, with N2OFF entitled to 25% of potential profits after loan repayment [2]. - The integration of the BESS is projected to yield incremental revenues of €100–120 per MW annually, representing a 40–50% increase compared to load shifting alone [3]. Project Details - The Green BESS Project will have a capacity of 107 MW / 214 MWh and aims to optimize electricity sales while providing additional grid services [1]. - The Melz project is part of N2OFF's flagship joint venture with Solterra, which received municipal approval to proceed with the statutory plan, with final approval expected in early 2026 [5]. Strategic Partnerships - N2OFF is collaborating with Solterra Renewable Energy Ltd. to accelerate the development of renewable energy projects across Europe, including multiple BESS projects in Italy and Poland [6][7]. Market Position - Entrix, a partner in the project, has a strong presence in the European energy market, managing over 2.4 GW and 7 GWh of battery storage assets [8].

As filed with the Securities and Exchange Commission on August 6, 2025 (Exact name of registrant as specified in its charter) incorporation or organization) Classification Code Number) Identification Number) Registration No. 333-______ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 N2OFF, INC. Nevada 2000 26-4684680 (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer HaPardes 134 (Meshek Sander) Nev ...

As filed with the Securities and Exchange Commission on August 6, 2025 Registration No. 333-______ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 N2OFF, INC. (Exact name of registrant as specified in its charter) incorporation or organization) Classification Code Number) Identification Number) Nevada 2000 26-4684680 (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer HaPardes 134 (Meshek Sander) Nev ...

Core Viewpoint - N2OFF, Inc. is increasing its investment in a 111 MWp solar photovoltaic project in Melz, Germany, to integrate a 40–60 MWp battery energy storage system (BESS), aiming to enhance its renewable energy business and project capacity [1][2][5] Company Overview - N2OFF, Inc. is a clean tech company focused on sustainable solutions for solar energy and agri-tech, recently entering the solar PV market and planning to fund the current project with a total capacity of 111 MWp [6] Project Details - The Melz project received approval from the Melz Municipal Committee on December 31, 2024, to include the project in its statutory plan, moving towards ready-to-build status by early 2026 [2] - The integration of a 40–60 MWp BESS is intended to improve the facility's ability to store excess solar energy and manage electricity purchases and sales effectively [4] Market Insights - The battery energy storage systems market in Germany is projected to reach a revenue of US$ 2,271 million by 2030, with a compound annual growth rate of 30.7% from 2024 to 2030 [3] Strategic Collaborations - N2OFF is collaborating with Solterra Renewable Energy Ltd. to accelerate the development of renewable energy facilities in Europe, including projects in Sicily, Albania, and Poland [5]